“We are confident that our findings offer the possibility to stop or prevent the disease’s destruction of nerve cells and the formation of deposits,” Probiodrug co-founder Hans-Ulrich Demuth told the paper.
But it will take at least seven years of clinical tests and development before the Halle-based company can market the product to people with the common and devastating form of dementia that effects the elderly, he said.
The company has taken out more than 27 patents to protect their work on the Alzheimer’s drug.
Please whitelist us to continue reading.